Form 4: BIO-TECHNE Director Sells Shares After Option Exercise
Insider Transaction Report
BIO-TECHNE Director Robert V. Baumgartner exercised stock options and subsequently sold 17,040 shares of common stock.
Summary
- Director Robert V. Baumgartner exercised 17,040 stock options for BIO-TECHNE Corp (TECH) common stock at an exercise price of $21.84 per share on August 25, 2025.
- Concurrently, Mr. Baumgartner sold 17,040 shares of BIO-TECHNE common stock at a weighted average price of $56.21 per share.
- The sales occurred in multiple transactions with prices ranging from $55.97 to $56.34.
- Following these transactions, Mr. Baumgartner's direct beneficial ownership of common stock is 44,863 shares.
- Mr. Baumgartner retains various stock options with exercise prices ranging from $25.30 to $128.81 and expiration dates extending up to October 24, 2034.
Sentiment
Score: 5
Explanation: Neutral. This is a routine insider transaction (exercise and sell) and does not inherently indicate positive or negative sentiment about the company's future prospects. It's a personal financial decision for liquidity or tax planning.
Positives
- The director realized a significant profit by exercising options at $21.84 and selling shares at a weighted average price of $56.21.
- The transaction demonstrates the value of the company's equity compensation program for its directors.
Negatives
- A director selling shares, even for routine purposes, can sometimes be perceived negatively by investors as it reduces their direct equity stake.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's operations or financial performance.
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction and does not provide information directly related to broader industry trends or competitors. It reflects an individual director's personal stock management and liquidity planning.
Comparison to Industry Standards
- This filing is a standard Form 4 for insider transactions, adhering to SEC disclosure requirements. It does not contain information that allows for a comparison of company performance or project results against industry benchmarks or specific comparable companies.
Stakeholder Impact
- Shareholders: The sale by a director is a common practice for liquidity or tax planning. While it reduces the director's direct equity stake, the remaining beneficial ownership still aligns the director with shareholder interests. The transaction itself does not indicate a change in company fundamentals.
Next Steps
- One block of options (3,511 shares) vests on the earlier of the one-year anniversary of the grant date (October 24, 2024) or the date of Bio-Techne's 2025 annual meeting of shareholders.
Key Dates
| Date | Description |
|---|---|
| 10/29/2016 | Date exercisable for 17,040 stock options with an exercise price of $21.84. |
| 10/26/2017 | Date exercisable for 15,940 stock options with an exercise price of $25.30. |
| 10/25/2018 | Date exercisable for 12,500 stock options with an exercise price of $31.26. |
| 10/24/2019 | Date exercisable for 7,592 stock options with an exercise price of $44.96. |
| 10/24/2020 | Date exercisable for 8,044 stock options with an exercise price of $50.41. |
| 10/28/2021 | Date exercisable for 6,028 stock options with an exercise price of $63.92. |
| 10/27/2022 | Date exercisable for 2,532 stock options with an exercise price of $128.81. |
| 10/26/2023 | Date exercisable for 3,460 stock options with an exercise price of $73.94. |
| 10/24/2024 | Grant date for 3,511 stock options with an exercise price of $68.37; also the earliest vesting date for these options. Date exercisable for 3,937 stock options with an exercise price of $61.51. |
| 08/25/2025 | Date of option exercise and subsequent sale of common stock. |
| 08/27/2025 | Date the Form 4 was signed by the attorney-in-fact. |
| 10/28/2025 | Expiration date for 17,040 stock options. |
| 10/26/2026 | Expiration date for 15,940 stock options. |
| 10/26/2027 | Expiration date for 12,500 stock options. |
| 10/25/2028 | Expiration date for 7,592 stock options. |
| 10/24/2029 | Expiration date for 8,044 stock options. |
| 10/29/2030 | Expiration date for 6,028 stock options. |
| 10/28/2031 | Expiration date for 2,532 stock options. |
| 10/27/2032 | Expiration date for 3,460 stock options. |
| 10/26/2033 | Expiration date for 3,937 stock options. |
| 10/24/2034 | Expiration date for 3,511 stock options. |
Recommendation
holdThis Form 4 filing details a routine exercise of stock options and subsequent sale of shares by a director for personal financial management. It does not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should consider this a neutral event and maintain their current position based on broader company fundamentals and market analysis.
Keywords
BIO-TECHNE, TECH, Form 4, Insider Transaction, Stock Options, Director, Share Sale, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.